阿托伐他汀对腹膜透析患者微炎症的干预作用

Effects of atorvastatin on microinflammatory process in peritoneal dialysis patients

目的:观察阿托伐他汀对腹膜透析患者微炎症状态的影响。方法:以东莞市人民医院肾内科40例稳定的腹膜透析患者为研究对象,治疗组患者分别于治疗前及阿托伐他汀治疗12周后,空腹抽血查血脂,包括:血清总胆固醇脂、低密度脂蛋白(LDL)和甘油三酯;检测炎症指标:血清高敏C反应蛋白(hs-CRP)、白介素6(IL一6)和肿瘤坏死因子(TNF-α)。结果:腹膜透析患者存在高血脂和高炎症状态,经过阿托伐他汀治疗12周后,腹膜透析患者的血清总胆固醇脂、低密度脂蛋白和甘油三酯明显下降(P【0.05),而炎症因子hs—CRP、IL-6和TNF-α水平也显著降低,与治疗前比较,有显著性差异(P【0.05)。结论:阿托伐他汀不但有显著的降血脂作用,还能明显改善腹膜透析患者的微炎症状态。

Objective:to investigate effects of atorvastatin on micro-inflammatory process in peritoneal dialysis patients. Methods:Fourty cases of stable peritoneal dialysis patients of Dongguan People Hospital were all treated with atorvastatin,before and 12 weeks after the treatment of atorvastatin,fasting blood lipid investigation including total serum cholesterol、Low-density lipoprotein(LDL)、triglycerides and inflammation indicators including serum high-sensitivity C-reactive protein(hs-CRP)、 interleukin-6(IL-6)and tumor necrosis factor(TNF-α) were all measured. Results: peritoneal dialysis patients were all in high blood fat and high inflammation state.After 12 weeks treatment of atorvastatin,patients’serum total cholesterol fat,low-density lipoprotein and triglycerides decreased significantly(P<0.05),and inflammatory factor including hs-CRP,IL-6 and TNF-α levels were significantly lower also,compared with the pre-treatment,the difference was significant(P<0.05).Conclusion:Atorvastatin is not only significant for Hypolipidemic but alos can significantly improve the micro-inflammatory state of peritoneal dialysis patients.